A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. (NCT07652658)
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
🩺 Plain-English Summary (8th-Grade Level)
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Who can join: Review the eligibility criteria below.
Location: Research Site — Birmingham, Alabama
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (190 Sites)
Showing the first 25 of 190 sites.
- Research Site — Birmingham, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Phoenix, Arizona
- Research Site — Loma Linda, California
- Research Site — Los Angeles, California
- Research Site — Newport Beach, California
- Research Site — Sacramento, California
- Research Site — Stanford, California
- Research Site — Aurora, Colorado
- Research Site — Denver, Colorado
- Research Site — Ocala, Florida
- Research Site — Weston, Florida
- Research Site — Atlanta, Georgia
- Research Site — Boise, Idaho
- Research Site — Champaign, Illinois
- Research Site — Chicago, Illinois
- Research Site — Kansas City, Kansas
- Research Site — Lexington, Kentucky
- Research Site — Baltimore, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Greensboro, North Carolina
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis (IPF)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — Birmingham, Alabama
- Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis — Denver, Colorado
- A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension — Norfolk, Virginia
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Palm Spring, California
- The Genetics of Pulmonary Fibrosis — Aurora, Colorado
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
Explore by condition: All Idiopathic Pulmonary Fibrosis (IPF) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.